US court passes order against Lupin Ltd in Myrbetriq® patent case

The United States District Court for the District of Delaware has passed an order in the matter of Myrbetriq® patent case.

In respect of Lupin's generic products 'Mirabegron', Astellas Pharma had filed a patent infringement case against Lupin.

On April 15, 2025, the Court ruled in favor of Astellas Pharma regarding the validity of its U.S. Patent No. 10,842,780 ("the '780 patent"). The Court noted that the issues of whether Lupin's products infringe the 780 patent, damages, and any additional invalidity theories will be litigated at a consolidated jury trial in 2026.

As on now, based on the Court Order, there are no material financial implications. The Company believes it has a strong case and is evaluating further legal action in the matter.

Shares of Lupin Limited was last trading in BSE at Rs. 1935.80 as compared to the previous close of Rs. 2012.05. The total number of shares traded during the day was 29970 in over 3103 trades.

The stock hit an intraday high of Rs. 2027.00 and intraday low of 1920.05. The net turnover during the day was Rs. 58559241.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Myrbetriq PatentCase USDistrictCourt Order